Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received for publication March 29, 2020
- Accepted for publication June 4, 2020
- Published online January 19, 2021.
Article Versions
- previous version (July 9, 2020 - 13:00).
- You are viewing the most recent version of this article.
Copyright & Usage
© 2021 by the Society of Nuclear Medicine and Molecular Imaging.
Author Information
- Johannes Czernin,
- Kyle Current,
- Christine E. Mona,
- Lea Nyiranshuti,
- Firas Hikmat,
- Caius G. Radu and
- Katharina Lückerath
- Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California
- For correspondence or reprints contact: Katharina Lückerath, UCLA, 650 Charles E. Young Dr. S., Los Angeles, CA 90095. E-mail: klueckerath{at}mednet.ucla.edu
Statistics from Altmetric.com
Cited By...
Article usage
Jump to section
Related Articles
Cited By...
- Current Status of Prostate-specific Membrane Antigen-targeted Alpha Radioligand Therapy in Prostate Cancer
- Targeted {alpha}-Therapy Using 225Ac Radiolabeled Single-Domain Antibodies Induces Antigen-Specific Immune Responses and Instills Immunomodulation Both Systemically and at the Tumor Microenvironment
- Targeted {alpha}-Therapy Using 225Ac Radiolabeled Single-Domain Antibodies Induces Antigen-Specific Immune Responses and Instills Immunomodulation Both Systemically and at the Tumor Microenvironment
- Combined Targeted Radiopharmaceutical Therapy and Immune Checkpoint Blockade: From Preclinical Advances to the Clinic
- mCRPC Patients Receiving 225Ac-PSMA-617 Therapy in the Post-Androgen Deprivation Therapy Setting: Response to Treatment and Survival Analysis
- Response to Combined Peptide Receptor Radionuclide Therapy and Checkpoint Immunotherapy with Ipilimumab Plus Nivolumab in Metastatic Merkel Cell Carcinoma
- Mechanisms of Resistance to Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy in a Mouse Model of Prostate Cancer